Keystone Financial Planning Inc. Sells 948 Shares of Sanofi $SNY

Keystone Financial Planning Inc. cut its stake in Sanofi (NASDAQ:SNY) by 4.2% in the 2nd quarter, Holdings Channel reports. The firm owned 21,844 shares of the company’s stock after selling 948 shares during the period. Keystone Financial Planning Inc.’s holdings in Sanofi were worth $1,055,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SNY. Accent Capital Management LLC bought a new position in shares of Sanofi in the 1st quarter worth about $29,000. Eastern Bank grew its position in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in Sanofi during the 2nd quarter valued at about $28,000. Golden State Wealth Management LLC boosted its holdings in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after acquiring an additional 545 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new stake in shares of Sanofi during the 1st quarter valued at about $33,000. 14.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SNY. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Up 4.3%

Shares of SNY opened at $51.64 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $48.65 and a 200-day moving average price of $49.55. The firm has a market capitalization of $126.80 billion, a P/E ratio of 12.41, a P/E/G ratio of 1.20 and a beta of 0.51. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business’s revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.73 earnings per share. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.